申请人:ESTEVE PHARMACEUTICALS, S.A.
公开号:EP3858439A1
公开(公告)日:2021-08-04
The present invention relates to new compounds that show pharmacological activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels, and the µ-opiod receptor (MOR or mu-opioid). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments.
本发明涉及对电压门控钙通道(VGCC)的亚单位α2δ,特别是对电压门控钙通道的α2δ-1亚单位或对电压门控钙通道(VGCC)的亚单位α2δ以及µ-阿片受体(MOR或μ-阿片)显示药理活性的新化合物。该发明还涉及所述化合物的制备方法,以及包含它们的组合物,以及它们作为药物的用途。